

Increased Serum Leptin Protects From Adiposity Despite the Increased Glucose Uptake in White Adipose Tissue in Mice Lacking p85 α Phosphoinositide 3-Kinase

Yasuo Terauchi,^{1,2} Junji Matsui,¹ Junji Kamon,¹ Toshimasa Yamauchi,^{1,2} Naoto Kubota,^{1,2,3} Kajuro Komeda,⁴ Shinichi Aizawa,⁵ Yasuo Akanuma,^{2,6} Motowo Tomita,⁷ and Takashi Kadowaki^{1,2,3}

Mice lacking the p85 α regulatory subunit of phosphoinositide (PI) 3-kinase (Pik3r1^{-/-}) showed increased glucose uptake in white adipose tissue (WAT) and skeletal muscle due to increased phosphatidylinositol (3,4,5)-triphosphate [PtdIns(3,4,5)P₃] production and on a normal diet had a body weight and fat mass similar to wild-type mice. After 3 months on a high-fat diet, Pik3r1^{-/-} mice still had increased insulin sensitivity and better glucose tolerance than wild-type mice, but showed markedly greater increases in body weight and WAT mass than wild-type mice. On the normal diet, serum leptin levels of Pik3r1^{-/-} mice were significantly higher than in wild-type mice as a result of increased leptin secretion from adipocytes, presumably due to the increased PtdIns(3,4,5)P₃ production in adipocytes. Leptin (5 μ g/g body wt per day) caused a reduction in food intake and decrease in body weight by the wild-type mice as well as Pik3r1^{-/-} mice, suggesting Pik3r1^{-/-} mice having leptin sensitivity similar to wild-type mice. The slightly increased serum leptin compensated for the increased glucose uptake by adipocytes in Pik3r1^{-/-} mice, thereby preventing adiposity on the normal diet. On the high-fat diet, leptin (5 μ g/g body wt per day) failed to decrease food intake or body weight in either genotype, indicating that both genotypes had indeed become severely leptin resistant. Consequently, leptin secretion was unable to sufficiently compensate for the severe leptin resistance caused by the high-fat diet, thereby failing to prevent obesity in Pik3r1^{-/-} mice. Our findings suggest that primary increase in serum leptin on the normal diet play a role in the protection from adiposity in Pik3r1^{-/-} mice. *Diabetes* 53:2261–2270, 2004

From the ¹Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; ²Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation, Kawaguchi, Japan; the ³National Institute of Health and Nutrition, Tokyo, Japan; the ⁴Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan; the ⁵Laboratory for Vertebrate Body Plan, Center for Developmental Biology, RIKEN, Kobe, Japan; the ⁶Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan; and the ⁷Department of Physiological Chemistry, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan.

Address correspondence and reprint requests to Takashi Kadowaki, MD, PhD, Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail: kadowaki-3im@h.u-tokyo.ac.jp.

Received for publication 1 May 2003 and accepted in revised form 20 May 2004. GFAT, glutamine:fructose-6-phosphate amidotransferase; GTT, glucose tolerance test; HPLC, high-performance liquid chromatography; IRS, insulin receptor substrate; KRBH, Krebs Ringer bicarbonate buffer; PI, phosphoinositide; PMSF, phenylmethylsulfonyl fluoride; PtdIns(3,4,5)P₃, phosphatidylinositol (3,4,5)-triphosphate; WAT, white adipose tissue.

© 2004 by the American Diabetes Association.

Obesity is defined as a state of pathophysiologically increased adipose mass and is closely linked to major diseases, such as diabetes, hyperlipidemia, hypertension, and cardiovascular disease (1). The prevalence of obesity, which often develops in adulthood, is increasing sharply in both Western countries and Japan, and the increase can be explained by drastic changes in lifestyle, such as a high-fat diet and sedentary lifestyle. Although adipocytes were previously viewed as passive participants in the pathogenesis of obesity, they have recently been recognized as playing a more active role in the regulation of energy homeostasis and body composition (1), and rapid advances are now being made in our knowledge of the mechanisms whereby many biological molecules secreted by adipocytes play a physiological role in the regulation of body weight and glucose homeostasis.

Leptin is a protein encoded by the obese gene (*ob*) and is synthesized and released in response to increased energy storage in adipose tissue (2). Leptin is an adiposity signal that acts on the hypothalamus, where it stimulates catabolic effector pathways and inhibits anabolic effector pathways, leading to decreased body weight and increased insulin sensitivity (3). The insulin signaling pathway and phosphoinositide (PI) 3-kinase (PI 3-kinase) have been suggested to be involved in the regulation of leptin production and secretion (4–6). Glucose utilization by adipocytes (7) and the hexosamine biosynthetic pathway (8,9) have been suggested to be key factors linking leptin production and secretion to body weight mass and energy availability. In fact, mice overexpressing the rate-limiting enzyme for hexosamine synthesis, glutamine:fructose-6-phosphate amidotransferase (GFAT), in muscle and fat have been shown to be hyperleptinemic (10,11). Moreover, in acute glucosamine and glucose infusion experiments (9), plasma leptin levels were found to be increased 2.5- to 3.0-fold compared with the control animals, whereas adipose tissue leptin levels were increased by only 50%. These results suggest that insulin, glucose metabolism, and hexosamine flux in fat regulate leptin synthesis and secretion, although it remains to be determined whether they are physiological regulators in vivo.

Adiponectin is another biological molecule secreted by adipocytes and was identified independently by four groups using different approaches (12–15). Mouse cDNAs

for adiponectin have also been termed Acrp30 (13) and AdipoQ (14). Adiponectin expression and plasma level have been reported to be significantly reduced in obese/diabetic mice and humans (14,16,17). It was reported that a proteolytic cleavage product of Acrp30 increases fatty acid oxidation in muscle and causes weight loss in mice (18), and we (19) and others (20) have recently reported that adiponectin is a potent insulin-sensitizing hormone linking adipose tissue and whole-body glucose metabolism. Thus, adiponectin may contribute to the suppression of obesity and insulin resistance. Importantly, adiponectin is reportedly produced and secreted in a PI 3-kinase-dependent manner (21).

P85 α is a regulatory subunit of PI 3-kinase that dimerizes the p110 catalytic subunit. Insulin activates PI 3-kinase by tyrosine phosphorylation of insulin receptor substrates (IRSs), such as IRS-1, and subsequent binding of p85 α associated with p110 (22,23). We generated mice lacking only the p85 α isoform of the *Pik3r1* gene (24–26) (*Pik3r1*^{-/-}) and found that they exhibited increased insulin sensitivity and hypoglycemia due to increased glucose transport in skeletal muscle and adipocytes (27). This phenotype can be explained by the fact that insulin-dependent generation of phosphatidylinositol (3,4,5)-triphosphate [PtdIns(3,4,5)P₃] is increased in *Pik3r1*^{-/-} mice in vivo (27). Mice lacking all three isoforms of *Pik3r1* also were shown to display hypoglycemia, lower insulin levels, and increased glucose tolerance (28), confirming the findings in our previous study (27). Importantly, insulin-stimulated PtdIns(3,4,5)P₃ production was prolonged in the knockout animals (29).

Selective overexpression of GLUT4 in the adipose tissue in mice has been shown to lead to increased glucose uptake by adipose tissue and to adiposity (30), demonstrating that adiposity can be promoted by increased glucose uptake and lipogenesis by adipocytes. On a normal diet, however, *Pik3r1*^{-/-} mice have normal body weight and adipose tissue mass despite the increased glucose uptake by adipose tissue (27). Interestingly, on a high-fat diet, the knockout animals became markedly obese compared with wild-type mice. We therefore attempted to identify the mechanisms by which *Pik3r1*^{-/-} mice maintain a normal body weight on a normal diet and became obese on the high-fat diet, as compared with wild-type mice.

RESEARCH DESIGN AND METHODS

Pik3r1^{+/-} mice (C57BL/6J and CBA background) were generated as described previously (27). They had been backcrossed with C57BL/6J mice more than three times, and because their genetic background was not completely homogeneous, female offspring obtained from intercrosses of *Pik3r1*^{+/-} mice were analyzed in this study. The animals were given free access to water and ordinary laboratory or high-fat diet and received standard animal care according to our institutional guidelines.

Measurement of serum parameters and in vivo glucose homeostasis. Glucose, insulin, and leptin levels were determined with a Glucose Test Sensor (Sanwa Kagaku Kenkyujo, Nagoya, Japan), an insulin kit (BIOTRAK; Amersham Life Science), and the Quantikine M Mouse Leptin Immunoassay kit (R&D Systems), respectively, according to the manufacturer's instructions. The glucose tolerance test (GTT) and insulin tolerance test were carried out according to previously described methods (27,31). The insulin resistance index was calculated by multiplying the fasting blood glucose level (mg/dl) by the fasting insulin level (ng/ml).

Histological and immunohistochemical analysis and determination of adipocyte size. Adipose tissue was fixed with formaldehyde, and after cutting 10- μ m sections and mounting them on glass slides, they were stained

with hematoxylin and eosin. White adipocyte areas were measured in 300 or more cells per mouse in each group, as described elsewhere (32).

Assessment of the effects of intraperitoneal leptin administration. Leptin (Peprro Tech EC) was administered as a daily intraperitoneal injection of 5 μ g/g body wt per day to wild-type and *Pik3r1*^{-/-} mice on each of the diets, and isotonic PBS was administered to controls. Changes in food intake and body weight were measured to assess the effects of leptin (32).

RNA preparation, Northern blot analysis, and RNase protection assay. Total RNA was prepared from white adipose tissue (WAT) by using TRIzol Reagent Total RNA isolation reagent (Gibco/BRL). Northern blot analysis was performed according to a standard protocol. RNase protection assay to measure leptin and GFAT mRNAs was performed by using HySpeed™ RPA (Ambion), as described previously (32). The leptin cRNA transcript is 615-bp long, whereas the RNase-protected product is 517-bp long (corresponding to nucleotides 50–566 of the mouse sequence) (Genebank U18812). The GFAT cRNA transcript is 615-bp long, whereas the RNase-protected product is 546-bp long (corresponding to nucleotides 1,469–2,014 of the mouse sequence) (Genebank U00932). Cyclophilin expression was used to normalize leptin or GFAT expression in each sample.

Determination of leptin content and leptin secretion. To determine the leptin contents of perimetric fat pads, tissue fragments were immediately placed in extraction buffer A (0.3 mol/l NaCl, 1 mmol/l EDTA, 0.05 mmol/l Tris-HCl, pH 7.4, 1% Triton X-100, and 1 mmol/l phenylmethylsulfonyl fluoride [PMSF]) and sonicated. After removing cell debris by repeated centrifugation at 15,000g at 4°C, the protein concentration and leptin concentration in the buffer were determined with a protein assay kit (BioRad) and the Quantikine M Mouse Leptin Immunoassay kit, respectively. Leptin content was calculated as nanogram of leptin per milligram of protein.

To obtain tissue samples for the leptin secretion experiment, perimetric fat pads were dissected into proximal and distal segments during removal from the animal and then further sectioned into several pieces in Krebs Ringer bicarbonate buffer (KRBH) (120 mmol/l NaCl, 4 mmol/l KH₂PO₄, 1 mmol/l MgSO₄, 1 mmol/l CaCl₂, 10 mmol/l NaHCO₃, and 30 mmol/l HEPES, pH 7.4) containing 0.5% BSA (Fraction V) (5). Each sample (~100 mg) consisted of two proximal pieces and two distal pieces, thereby ensuring that each sample contained a mixture of large and small cells, since leptin levels appear to correlate with adipose cell size. Samples were incubated with or without 100 nmol/l insulin for 1 h. To assess the inhibition of insulin-induced leptin secretion by wortmannin, WAT was incubated with 100 nmol/l wortmannin for 20 min before insulin stimulation and during insulin stimulation. The amount of leptin in the medium was measured in the presence or absence of 100 nmol/l insulin or 100 nmol/l wortmannin using the Quantikine M Mouse Leptin Immunoassay kit.

Measurement of glucosamine metabolites. Uridinediphospho-glucose (UDP-Glc), uridinediphospho-galactose (UDP-Gal), uridinediphospho-N-acetyl-glucosamine (UDP-GlcNAc), and uridinediphospho-N-acetyl-galactosamine (UDP-GalNAc) concentrations were determined by two sequential chromatographic separations and UV detection (33,34). Briefly, the first purification was performed on a solid-phase, strong anion-exchanging cartridge by using phosphate buffers of increasing molarity. This first purification allows partial separation of the two compounds of interest from nonpolar cellular and most polar intracellular substrates with optimal recoveries. UDP-GlcNAc and UDP-GalNAc coelute with UDP-Glc and UDP-Gal during the solid-phase extraction. The second step is a reverse-phase ion-pairing high-performance liquid chromatography (HPLC isocratic method on a C18 column. All HPLC analyses were performed on an HPLC system (TOSOH) by a reverse-phase ion-pairing isocratic method on a C18 column, namely, an Inertasil ODS-2 reverse-phase column (0.46 \times 15 cm). The mobile phase was 0.55 mol/l boric acid, 2 mol/l glycerol, 0.3 mmol/l hexadecyltrimethyl ammonium bromide, and 40% methanol (vol/vol) (35). Under our experimental conditions, the retention times for UDP-Glc, UDP-Gal, UDP-GlcNAc, and UDP-GalNAc were 38.0, 43.9, 35.5, and 42.5 min, respectively.

High-fat diet study. The composition of the normal diet (CLEA Rodent Diet CE-2; CLEA, Japan) was 50.7% (wt/wt) carbohydrate, 4.6% fat, 25.2% protein, 4.4% dietary fiber, 6.5% crude ash, 3.6% mineral mixture, 1% vitamin mixture, and 4% moisture. The composition of the high-fat diet was 32% safflower oil, 33.1% casein, 17.6% sucrose, 5.6% cellulose, 9.8% mineral mixture, 1.4% vitamin mixture, 0.5% DL-methionine (32,36).

Determination of adiponectin content, serum adiponectin, and adiponectin secretion. To determine the adiponectin contents of fat pads, tissue fragments were immediately placed in extraction buffer A and sonicated, and after removing cell debris by repeated centrifugation at 15,000g at 4°C, the protein concentration in the buffer was determined using a protein assay kit (BioRad). The same amounts of proteins were subjected to SDS-PAGE, followed by immunoblotting with the polyclonal antibody to GBP28 (human adiponectin) (15), as described elsewhere (27,37). The serum adi-

ponectin level was determined by immunoblotting with the antibody to GBP28. To measure the amounts of adiponectin secreted by adipose tissue, 100 mg of tissue fragments was incubated in KRBH buffer containing 0.5% BSA with or without insulin stimulation (100 nmol/l) for up to 60 min. To assess the inhibition of insulin-induced adiponectin secretion by wortmannin, adipose tissue was incubated with 100 nmol/l wortmannin for 20 min before insulin stimulation and during insulin stimulation. The amounts of adiponectin in the medium were measured by Western blotting.

Statistical analysis. Results are expressed as means \pm SE. Statistical analysis was performed using the Statview software system (Abacus Concepts, Berkeley, CA). Statistical differences were analyzed by using Student's *t* test for unpaired comparisons. A *P* value <0.05 was considered statistically significant.

RESULTS

Increased insulin sensitivity and normal body weight of *Pik3r1*^{-/-} mice on a normal diet. At 5 months of age on a normal diet, under fed conditions the blood glucose levels of *Pik3r1*^{-/-} mice were lower than those in wild-type mice (115 \pm 2 vs. 129 \pm 2 mg/dl, *P* < 0.01). A GTT showed that blood glucose levels of the *Pik3r1*^{-/-} mice were significantly lower than those of the wild-type mice, and the *Pik3r1*^{-/-} mice had significantly lower fasting insulin levels than those of the wild-type mice (data not shown). These findings were consistent with the results of our previous study that male *Pik3r1*^{-/-} mice showed increased insulin sensitivity (27). On the normal diet, the body weight (Fig. 1A), fat mass (Fig. 1B), and size of the adipocytes (Fig. 1C) of the *Pik3r1*^{-/-} mice were similar to those of the wild-type mice.

Increased serum leptin levels of *Pik3r1*^{-/-} mice on a normal diet. On a normal diet, the serum leptin levels of the *Pik3r1*^{-/-} mice were significantly higher than those of the wild-type mice (5.0 \pm 0.6 vs. 2.9 \pm 0.4 ng/ml, *P* < 0.01) (Fig. 2A), despite having similar body weight and fat mass. To determine whether the higher serum leptin levels in the *Pik3r1*^{-/-} mice were due to increased production, we investigated leptin expression in WAT. Northern blot analysis revealed indistinguishable levels of leptin expression in the *Pik3r1*^{-/-} and wild-type mice on a normal diet (Fig. 2B), and similar results were obtained by RNase protection assay (data not shown). Because the leptin content of the WAT was somewhat decreased in the *Pik3r1*^{-/-} mice compared with the wild-type mice (Fig. 2C), it is likely that leptin secretion was increased in the *Pik3r1*^{-/-} mice. We next assessed leptin secretion by isolated adipose tissue over a 60-min period. Although insulin did not increase leptin secretion by wild-type adipose tissue, it caused a robust increase in leptin secretion by *Pik3r1*^{-/-} adipose tissue (Fig. 2D). Wortmannin, a PI 3-kinase inhibitor, suppressed this effect in *Pik3r1*^{-/-} adipose tissue, suggesting that the increased leptin secretion was caused by increased PtdIns(3,4,5)P3 production in the *Pik3r1*^{-/-} adipocytes in response to insulin as compared with wild-type adipocytes, as we previously reported (27). When fractional leptin secretion was calculated by normalizing the amount of secreted leptin by the leptin content of WAT in the presence of insulin stimulation, *Pik3r1*^{-/-} adipose tissue was found to secrete more leptin than wild-type tissue (Fig. 2E).

UDP-GlcNAc level in *Pik3r1*^{-/-} adipose tissue was not increased. To determine the potential involvement of hexosamine pathway in the increased leptin secretion, we studied the hexosamine biosynthesis pathway (Fig. 3A). We noted a significantly (by 42%) lower level of GFAT




FIG. 1. Normal body weight and fat mass in *Pik3r1*^{-/-} on a normal diet. **A:** Body weight of 5-month-old wild-type and *Pik3r1*^{-/-} mice on a normal diet. Values are expressed as means \pm SE (wild-type, *n* = 45; *Pik3r1*^{-/-} mice, *n* = 38). **B:** Total weight of the WAT (perimetric, retroperitoneal, and perirenal fat pads) of wild-type and *Pik3r1*^{-/-} mice on the normal diet. Values are expressed as means \pm SE (*n* = 8). **C:** Adipocyte size of wild-type and *Pik3r1*^{-/-} mice on the normal diet. Values are expressed as means \pm SE (*n* = 4).

expression in the WAT of the *Pik3r1*^{-/-} mice on the normal diet than in wild-type mice (Fig. 3B). We next measured UDP-Glc and UDP-GlcNAc, the end product of the hexosamine biosynthesis pathway, in WAT. The UDP-GlcNAc level was increased by only 18% in *Pik3r1*^{-/-} mice compared with wild-type mice, whereas the UDP-Glc level was increased by 56%, albeit not significantly (Fig. 3C). It seems likely that a combination of potentially increased




FIG. 2. Increased leptin secretion by *Pik3r1*^{-/-} adipose tissues associated with increased PI 3-kinase activity on the normal diet. **A:** Serum leptin levels of wild-type and *Pik3r1*^{-/-} mice on the normal diet. Values are expressed as means \pm SE of data obtained from wild-type mice ($n = 42$) and *Pik3r1*^{-/-} mice ($n = 36$). **B:** Leptin expression levels of wild-type and *Pik3r1*^{-/-} mice on the normal diet. Northern blot analysis of total RNA from the WAT of each genotype. Representative images are shown in upper panel. Data have been normalized to 36B4 and calculated as fold intensity. Bars represent means \pm SE (wild-type, $n = 7$; *Pik3r1*^{-/-} mice, $n = 8$). **C:** Leptin content of perimetric WAT in wild-type and *Pik3r1*^{-/-} mice on the normal diet. Values are expressed as means \pm SE ($n = 5$). **D:** Leptin secretion by the adipose tissue of wild-type and *Pik3r1*^{-/-} mice on the normal diet. The amount of leptin in the medium was measured after incubation for 60 min in the presence or absence of 100 nmol/l insulin or 100 nmol/l wortmannin. Experiments were carried out three times, and similar results were obtained. Therefore, the results were collected, and values are expressed as means \pm SE ($n = 9-12$) (ng of leptin secreted by 1 g of adipose tissue). **E:** Fractional leptin secretion by adipose tissue from wild-type and *Pik3r1*^{-/-} mice on the normal diet. The amount of leptin in the medium was measured in the presence of 100 nmol/l insulin at the times indicated. Experiments were carried out twice, and similar results were obtained. Therefore, the results were collected, and values are shown as fractional leptin secretion (ng of leptin secreted in the medium/ng of leptin content of adipose tissue; %) (means \pm SE, $n = 12$). **F and G:** Effect of intraperitoneal leptin administration on the food intake and body weight of wild-type and *Pik3r1*^{-/-} mice on the normal diet. Mice received a daily intraperitoneal injection of either leptin ($5 \mu\text{g} \cdot \text{g}^{-1} \cdot \text{day}^{-1}$) (lep +) or isotonic sodium chloride solution (lep -). After administration for 5 days, changes in food intake (**F**) and body weight per day (gram) (**G**) were measured. Values are expressed as means \pm SE of the values obtained in each group ($n = 9$).

glucose influx, as evidenced by the increased UDP-Glc levels, and downregulation of GFAT expression caused only a minimal increase in UDP-GlcNAc levels in WAT and that the increased leptin secretion by *Pik3r1*^{-/-} WAT cannot be satisfactorily explained by the hexosamine flux. **Increased serum leptin compensated for the increased glucose uptake by adipocytes, thereby preventing adiposity in *Pik3r1*^{-/-} mice on the normal diet.** On the normal diet, *Pik3r1*^{-/-} mice had a normal fat mass and body weight despite having higher serum leptin levels than the wild-type mice. These results can be interpreted as meaning that the *Pik3r1*^{-/-} mice were leptin resistant on the normal diet, because it took more leptin to maintain a fat mass similar to that of the wild-type mice.

To compare the sensitivity of the mouse groups on the normal diet to endogenous and exogenous leptin, we measured changes in the food intake and body weight of mice with or without leptin administration. On the normal diet the *Pik3r1*^{-/-} and wild-type mice had similar food intake (Fig. 2F). Leptin ($5 \mu\text{g/g}$ body wt per day by intraperitoneal injection), however, caused a 34% reduction ($P < 0.05$) in food intake in the wild-type mice and a 22% reduction (NS) in the *Pik3r1*^{-/-} mice. Leptin caused a 2.41% decrease in the body weight ($P < 0.01$) of the wild-type mice, but only a 0.78% decrease (NS) in the *Pik3r1*^{-/-} mice (Fig. 2G). Thus, *Pik3r1*^{-/-} mice had mild leptin resistance compared with wild-type mice, but the difference in leptin sensitivity between the two groups was




FIG. 3. Minimally increased UDP-GlcNAc in *Pik3r1*^{-/-} adipose tissue. **A:** Schematic representation of the hexosamine biosynthesis pathway. After glucose entry into adipose cells via the glucose transport system and rapid phosphorylation to glucose-6-phosphate (G-6-P), it is primarily utilized by the glycogen synthesis and glycolysis pathways. The hexosamine pathway receives ~1–3% of incoming glucose via conversion of fructose-6-phosphate (F-6-P) to glucosamine-6-phosphate (GlcN-6-P) by the rate-limiting enzyme GFAT. The principal end product of this pathway, UDP-GlcNAc, is the substrate for virtually all glycosylation pathways. **B:** Level of expression of GFAT mRNA in perimetric WAT from wild-type and *Pik3r1*^{-/-} mice on a normal diet. Data have been normalized to 36B4 and calculated as fold intensity. The bars represent means \pm SE ($n = 3$). **C:** Levels of UDP-GlcNAc and UDP-Glc in the adipose tissue of mice on the normal diet. The body weight of wild-type and *Pik3r1*^{-/-} mice was 25.3 ± 1.0 g ($n = 8$) and 27.1 ± 1.7 g ($n = 6$) (NS), respectively, and their serum leptin levels were 1.3 ± 0.7 and 4.4 ± 1.1 ng/ml, respectively ($P < 0.05$). The bars represent means \pm SE. * $P < 0.05$ vs. wild-type mice.

quite small. It therefore seems likely that primary increase in serum leptin compensated for the increased glucose uptake by adipocytes in *Pik3r1*^{-/-} mice, thereby maintaining normal body weight and food intake.

High-fat diet-induced obesity in *Pik3r1*^{-/-} mice. Both mouse groups were fed a normal diet until 5 months of age and were then fed either a normal or high-fat diet. We performed GTTs in wild-type and *Pik3r1*^{-/-} mice after 3 months on a normal or high-fat diet. The blood glucose levels during GTTs were higher in the wild-type mice on the high-fat diet than on the normal diet. This development of glucose intolerance was also observed in the *Pik3r1*^{-/-} mice on the high-fat diet, but their glucose tolerance was still much better than that of wild-type mice on the high-fat diet (Fig. 4A), and the *Pik3r1*^{-/-} mice had lower fasting insulin levels on the high-fat diet than the wild-type mice (Fig. 4B). On the high-fat diet, the insulin resistance index (calculated by multiplying the fasting blood glucose level by the fasting insulin level) of the *Pik3r1*^{-/-} mice was decreased by 63% compared with the wild-type mice (Fig. 4C). These results may be due to the increased hepatic insulin sensitivity in *Pik3r1*^{-/-} mice even on the high-fat diet compared with wild-type mice on the high-fat diet. Blood glucose levels 90 min after insulin injection in *Pik3r1*^{-/-} mice were significantly lower than in the wild-type mice (data not shown), suggesting *Pik3r1*^{-/-} mice to have better peripheral insulin sensitivity than wild-type mice. Thus, after 3 months on the high-fat diet, *Pik3r1*^{-/-} mice still showed increased insulin sensitivity and better glucose tolerance than the wild-type mice.

Next we studied the effect of the high-fat diet on body weight, fat mass, and adipocyte size. After 3 months on the normal diet (at 8 months of age), the body weight of the *Pik3r1*^{-/-} mice was similar to that of the wild-type mice (36.5 ± 1.7 vs. 35.0 ± 1.4 g, NS) (Fig. 4D). By contrast, after 3 months on the high-fat diet, *Pik3r1*^{-/-} mice showed markedly heavier body weight (49.1 ± 2.8 vs. 39.4 ± 1.5 g, $P < 0.01$) (Fig. 4C) and WAT mass (4.7 ± 0.5 vs. 3.4 ± 0.2 g, $P < 0.05$) (Fig. 4E) than wild-type mice, even though *Pik3r1*^{-/-} mice had body weight similar to that of wild-type mice on the normal diet. Although adipocyte size in both types of mice was significantly larger on the high-fat diet than on the normal diet, adipocyte size in the high-fat *Pik3r1*^{-/-} group was significantly larger than in the high-fat wild-type group (Fig. 4F). The number of adipocytes in both types of mice was similar whether on the normal or the high-fat diet (data not shown). Thus, the *Pik3r1*^{-/-} mice developed greater adiposity than the wild-type mice on the high-fat diet.

Leptin action in *Pik3r1*^{-/-} mice on the normal diet was abrogated on the high-fat diet. On a normal diet, the serum leptin levels of the *Pik3r1*^{-/-} mice were significantly higher than in the wild-type mice, despite similar body weight and fat mass. After 3 months on the high-fat diet, the leptin levels had risen to 45.0 ± 6.6 ng/ml in the *Pik3r1*^{-/-} mice and 26.7 ± 4.0 ng/ml in the wild-type mice ($P = 0.02$) (Fig. 5A), suggesting that both genotypes became leptin resistant on the high-fat diet as compared with the normal-diet groups and that the *Pik3r1*^{-/-} mice were more leptin resistant than wild-type mice on the




FIG. 4. High-fat (HF) diet-induced obesity in *Pik3r1*^{-/-} mice. **A** and **B**: Glucose tolerance in wild-type and *Pik3r1*^{-/-} mice after 3 months on the normal or high-fat diet. Plasma glucose levels (**A**) were measured at the times indicated. Fasting insulin levels (**B**) were also measured. Values are expressed as means \pm SE of the data obtained from wild-type mice on the normal diet (squares, $n = 11$), wild-type mice on the high-fat diet (circles, $n = 9$), *Pik3r1*^{-/-} mice on the normal diet (diamonds, $n = 10$), and *Pik3r1*^{-/-} mice on the high-fat diet (triangles, $n = 5$). # $P < 0.05$ vs. wild-type mice on the high-fat diet. **C**: Insulin sensitivity index, calculated by multiplying the fasting glucose level by the fasting insulin level, in wild-type and *Pik3r1*^{-/-} mice after 3 months on the normal or high-fat diet. **D**: Changes in body weight of wild-type and *Pik3r1*^{-/-} mice. Both mouse groups were fed a normal diet until 5 months of age and then fed either a normal or high-fat diet. Values are expressed as means \pm SE ($n = 10$ – 14). **E**: Total weight of the WAT (perimetric, retroperitoneal, and perirenal fat pads) of wild-type and *Pik3r1*^{-/-} mice after 3 months on the high-fat diet. Values are expressed as means \pm SE ($n = 8$). **F**: Adipocyte size of wild-type and *Pik3r1*^{-/-} mice after 3 months on the high-fat diet. Values are expressed as means \pm SE ($n = 1,200$). * $P < 0.05$; ** $P < 0.01$.

high-fat diet. To compare leptin sensitivity and action in the high-fat diet groups, we measured changes in food intake and body weight in mice injected and not injected with leptin. After 12 weeks on the high-fat diet, *Pik3r1*^{-/-} mice showed greater food intake than the wild-type mice (Fig. 5B) and a body weight gain similar to that of the wild-type mice (Fig. 5C). Although leptin administration (5 μ g/g body wt per day) decreased food intake in both genotypes on the normal diet (Fig. 2F), it did not decrease food intake or body weight in either genotype on the

high-fat diet, indicating that both genotypes had indeed become severely leptin resistant on the high-fat diet. Thus, the balanced leptin action seen in *Pik3r1*^{-/-} mice on the normal diet appears to be abrogated by the severe leptin resistance on the high-fat diet.

Differences in body weight and fat mass may be important confounding factors in the high-fat studies. We therefore compared weight-matched groups to avoid these factors. To this end, we compared wild-type mice on the high-fat diet (33.8 ± 1.8 g, $n = 8$) with *Pik3r1*^{-/-} mice on




FIG. 5. Balanced leptin action in *Pik3r1*^{-/-} mice on the normal diet abrogated on the high-fat (HF) diet by severe leptin resistance. **A:** Serum leptin levels of wild-type and *Pik3r1*^{-/-} mice after 3 months on the normal and high-fat diet. Values are expressed as means \pm SE of the data obtained from the wild-type mice on the normal diet ($n = 42$), *Pik3r1*^{-/-} mice on the normal diet ($n = 36$), wild-type mice on the high-fat diet ($n = 15$), and *Pik3r1*^{-/-} mice on the high-fat diet ($n = 10$). **B and C:** Effect of intraperitoneal leptin administration on the food intake and body weight of wild-type and *Pik3r1*^{-/-} mice after 3 months on the high-fat diet. Mice received either a daily intraperitoneal injection of either leptin ($5 \mu\text{g} \cdot \text{g}^{-1} \cdot \text{day}^{-1}$) (lep +) or isotonic sodium chloride solution (lep -). After administration for 5 days, changes in food intake (**B**) and body weight (**C**) were measured. Values are expressed as means \pm SE of the data obtained from the respective mouse groups ($n = 4-7$). ** $P < 0.01$.

the high-fat diet ($34.7 \pm 1.4 \text{ g}$, $n = 9$) ($P = 0.71$). Serum leptin was 32.8 ± 4.0 vs. $49.2 \pm 5.7 \text{ ng/ml}$ ($P < 0.05$), respectively. Food intake was 0.066 ± 0.004 vs. $0.075 \pm 0.006 \text{ g} \cdot \text{g body wt}^{-1} \cdot 24 \text{ h}^{-1}$ ($P = 0.21$), respectively, and change in body weight was 0.92 ± 0.45 vs. $0.83 \pm 0.28 \text{ g} \cdot \text{g body wt}^{-1} \cdot 24 \text{ h}^{-1}$ (%) ($P = 0.87$), respectively. Thus, even weight-matched *Pik3r1*^{-/-} mice on the high-fat diet had significantly higher serum leptin levels than wild-type mice on the high-fat diet but showed food intake and body weight gain similar to those of wild-type mice on the high-fat diet. These results suggest that increased serum leptin in *Pik3r1*^{-/-} mice on the high-fat diet compared with wild-type mice on the high-fat diet is independent of body weight.

Increased serum adiponectin in *Pik3r1*^{-/-} mice as compared with wild-type mice. On a normal diet, expression of adiponectin was significantly increased by 90% in *Pik3r1*^{-/-} WAT compared with wild-type WAT (Fig. 6A), despite the two genotypes having similar body weight, WAT mass, and adipocyte size (Fig. 1C-E). The level of expression was decreased in both groups on the high-fat diet, consistent with previous reports (14,19). We next determined serum adiponectin levels by Western blotting. Serum adiponectin was detected as a 35-kDa protein (Fig. 6B, upper panel), and on the normal diet its level was approximately fourfold higher in the *Pik3r1*^{-/-} mice than in the wild-type mice (Fig. 6B, lower panel). WAT adiponectin content on the normal diet was increased by 60% in *Pik3r1*^{-/-} mice compared with wild-type mice ($P = 0.06$) (Fig. 6C). We then investigated adiponectin secretion by WAT in the presence and absence of insulin. Insulin-dependent adiponectin secretion after incubation for 60 min was significantly greater in *Pik3r1*^{-/-} tissue than wild-type tissue, and wortmannin suppressed this effect

(Fig. 6D). Taken together, these findings indicate that adiponectin secretion and adiponectin production are increased in *Pik3r1*^{-/-} WAT as a result of increased PtdIns(3,4,5)P3 production in the *Pik3r1*^{-/-} adipocytes, as compared with wild-type adipocytes, in response to insulin, as we previously reported (27). Thus, these findings raise the possibility that insulin-stimulated PI 3-kinase activation regulates serum adiponectin levels.

DISCUSSION

Selective overexpression of GLUT4 in the adipose tissue demonstrated that adiposity can be promoted by increased glucose uptake and lipogenesis by adipocytes (30). On a normal diet, *Pik3r1*^{-/-} mice have normal body weight and adipose tissue mass despite the increased glucose uptake by adipose tissue. In the present study, we attempted to identify the mechanisms by which *Pik3r1*^{-/-} mice maintained normal body weight on the normal diet. After 3 months on a high-fat diet, *Pik3r1*^{-/-} mice showed markedly greater increases in body weight and WAT mass than wild-type mice. On the normal diet, serum leptin levels of *Pik3r1*^{-/-} mice were significantly higher than in wild-type mice as a result of increased leptin secretion from adipocytes. *Pik3r1*^{-/-} mice had mild leptin resistance compared with wild-type mice, but the difference in leptin sensitivity between the two groups was quite small. It therefore seems likely that primary increase in serum leptin compensated for the increased glucose uptake by adipocytes in *Pik3r1*^{-/-} mice, thereby maintaining normal body weight and food intake. On the high-fat diet, the increased leptin secretion was insufficient to compensate for the leptin resistance caused by high-fat diet and thus failed to prevent obesity.




FIG. 6. Increased adiponectin production and secretion in *Pik3r1*^{-/-} WAT. **A:** Adiponectin expression levels in the perimetric WAT of wild-type and *Pik3r1*^{-/-} mice on the normal and high-fat (HF) diets. Data have been normalized to 36B4 and calculated as fold intensity. The bars represent means \pm SE ($n = 3$). **B:** Serum adiponectin levels of wild-type and *Pik3r1*^{-/-} mice on the normal diet. The serum adiponectin level was determined by Western blotting. Serum samples from five animals were collected for each genotype. Adiponectin was detected as a 35-kDa protein with anti-adiponectin antibody (upper panel). **C:** Adiponectin content of wild-type and *Pik3r1*^{-/-} mice on the normal diet. The same amounts of proteins were subjected to SDS-PAGE. Values are expressed as means \pm SE ($n = 10$). **D:** Adiponectin secretion by adipose tissues from wild-type and *Pik3r1*^{-/-} mice on the normal diet. The same amounts of adipose tissue fragments were preincubated in KRBH buffer containing 0.5% BSA for 20 min and then incubated for 60 min with or without insulin stimulation (100 nmol/l) or preincubated in KRBH buffer containing 0.5% BSA and 100 nmol/l wortmannin for 20 min and then incubated for 60 min with 100 nmol/l insulin. Values are expressed as fold stimulation compared with the respective groups without insulin stimulation. Bars represent means \pm SE ($n = 6-11$). * $P < 0.05$; ** $P < 0.01$.

On the normal diet, the serum leptin levels of the *Pik3r1*^{-/-} mice were increased as compared with wild-type mice (Fig. 2A), despite having similar body weight and fat mass (Fig. 1C and D). Assuming normal leptin sensitivity and normal glucose uptake by adipocytes on the normal diet, *Pik3r1*^{-/-} mice would be lean due to the increased leptin action, as reported in leptin transgenic mice (38). In marked contrast to their body weight being similar to that of wild-type mice on the normal diet, on the high-fat diet the *Pik3r1*^{-/-} mice showed markedly greater increases in body weight and WAT mass than the wild-type mice (Fig. 5C and D), a phenotype similar to that of IRS-2 knockout (IRS-2^{-/-}) mice (39,40) and neuron-specific insulin receptor knockout mice (41). How does the leptin resistance in these mice develop? Both insulin and leptin receptors are present in hypothalamic regions that control energy homeostasis, and insulin, like leptin, has been reported to hyperpolarize hypothalamic glucose-responsive neurons in lean rats by opening ATP-dependent potassium (K_{ATP}) channels (42,43). Hypothalamic K_{ATP} channel function has been suggested to be crucial to

physiological regulation of food intake and body weight, and involvement of PI 3-kinase in insulin signaling as well as leptin signaling pathways in hypothalamic neurons has been suggested (42,44).

Pik3r1^{-/-} mice exhibited increased glucose transport in adipocytes due to increased insulin-dependent generation of PtdIns(3,4,5)P3 in vivo (27). Insulin-stimulated PI 3-kinase activity associated with IRSs was mediated via p85 α in wild-type mice, whereas it was mediated via the p50 α isoform in *Pik3r1*^{-/-} mice, and this isoform switch was associated with an increase in insulin-induced generation of PtdIns(3,4,5)P3 in *Pik3r1*^{-/-} adipocytes. On the other hand, *Pik3r1*^{-/-} mice showed selective decrease in the number of mature B-cells due to markedly decreased PI 3-kinase activation (45). We observed abundant expression of the p50 α in T-cells of both *Pik3r1*^{-/-} mice and normal mice, whereas B-cells expressed only a low amount of this isoform. Thus, it seems likely that in vivo PI 3-kinase activity in respective tissue of *Pik3r1*^{-/-} mice is dependent on the relative existence of p50 α and p85 α . Western blot

analysis revealed that, while expression of p85 α was not altered among hypothalamus, WAT, and liver of wild-type mice, p50 α expression was by far lower in the hypothalamus than in the other two tissues (data not shown). It is therefore possible that disruption of p85 α PI 3-kinase results in decreased activation of PI 3-kinase in hypothalamic neurons, leading to leptin resistance in *Pik3r1*^{-/-} mice. In the future, hypothalamus-specific *Pik3r1* gene knockout should provide a genetic explanation for the role of PI 3-kinase in the hypothalamus.

After 3 months on the high-fat diet, both wild-type and *Pik3r1*^{-/-} mice became severely leptin resistant. In marked contrast to having a similar body weight to wild-type mice on the normal diet, on the high-fat diet *Pik3r1*^{-/-} mice showed greater increases in body weight and WAT mass than the wild-type mice (Fig. 4D and E). High-fat diet-induced leptin resistance abrogated the balanced leptin action in *Pik3r1*^{-/-} mice, leading to the obese phenotype. Thus, against a background of excess glucose transport into adipocytes caused by increased production of PtdIns(3,4,5)P3, a concomitant increase in leptin plays a physiological role in the suppression of adiposity due to excess glucose influx into adipocytes, and this should explain the difference between *Pik3r1*^{-/-} mice and adipose tissue-specific GLUT4 transgenic mice. While involvement of the insulin signaling pathway and PI 3-kinase has been suggested in the regulation of leptin production and secretion (4–6), under our experimental conditions, insulin increased leptin secretion by *Pik3r1*^{-/-} WAT via PI 3-kinase-dependent pathway (Fig. 2D). Studies on insulin exposure of isolated human adipose cells have generally not shown acute stimulation of leptin secretion either (46). The difference may be explained by the balance between PI 3-kinase activation in response to insulin and other antagonizing effects (47).

Because many biological molecules regulate food intake and energy expenditure in vivo, molecules other than leptin may contribute to the phenotype in *Pik3r1*^{-/-} mice on a normal diet, and we focused on adiponectin (19,20). We previously showed that adiponectin expression is negatively correlated with adipocyte size (19,48). Interestingly, however, on the normal diet adiponectin expression in WAT was increased in the *Pik3r1*^{-/-} mice as compared with wild-type mice (Fig. 6A), despite having similar body weight, WAT mass, and adipocyte size (Fig. 1C–E). Even more unexpectedly, adiponectin expression in WAT on the high-fat diet was higher in *Pik3r1*^{-/-} mice than in the wild-type mice (Fig. 6A), despite larger adipocyte size (Fig. 4E). Serum adiponectin was elevated in *Pik3r1*^{-/-} mice compared with wild-type mice (Fig. 6B), and insulin-dependent adiponectin secretion by *Pik3r1*^{-/-} WAT was significantly increased compared with secretion by wild-type WAT (Fig. 6D). Because adiponectin secretion has been demonstrated to be increased by insulin in a PI 3-kinase-dependent fashion (21), we interpreted these findings as indicating that the kinetics of adiponectin secretion are upregulated by the increased PtdIns(3,4,5)P3 production in *Pik3r1*^{-/-} adipocytes. Thus, insulin-stimulated PI 3-kinase activation not only increases adiponectin expression but also stimulates its secretion by adipocytes, leading to an elevation of serum adiponectin. It is possible that the increased serum adiponectin in *Pik3r1*^{-/-} mice

contributes to increased insulin sensitivity in peripheral tissues during both the normal and the high-fat diet in addition to a primary increase in PtdIns(3,4,5)P3 in adipocytes and presumably skeletal muscles in *Pik3r1*^{-/-} mice. To study the role of adiponectin in *Pik3r1*^{-/-} mice, we are now generating mice lacking adiponectin in addition to p85 α .

In summary, serum leptin was increased in *Pik3r1*^{-/-} mice due to increased secretion by WAT. Serum adiponectin was also increased in *Pik3r1*^{-/-} mice as a result of increased production and secretion. The slightly increased serum leptin compensated for the increased glucose uptake by adipocytes in *Pik3r1*^{-/-} mice, thereby preventing adiposity on the normal diet. The results of this study provide important biochemical links among the increased availability of nutrients, production of PIs in vivo, and serum leptin and adiponectin levels, all of which contribute to the regulation of fat storage and insulin sensitivity.

ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas [(2) 15081202] (Y.T.), a Grant-in-Aid for Creative Scientific Research (10NP0201) from the Japan Society for the Promotion of Science, a Grant-in-Aid for Scientific Research on Priority Areas (C), a Grant-in-Aid for the Development of Innovative Technology from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Health Science Research Grants (Research on Human Genome and Gene Therapy) from the Ministry of Health and Welfare (T.K.).

We thank Eri Yoshida-Nagata, Ayumi Nagano, Miharu Nakashima, and Hiroshi Chiyonobu for their excellent technical assistance and animal care.

REFERENCES

1. Spiegelman BM, Flier JS: Adipogenesis and obesity: rounding out the big picture. *Cell* 87:377–389, 1996
2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. *Nature* 372:425–432, 1994
3. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG: Central nervous system control of food intake. *Nature* 404:661–671, 2000
4. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Staels B, Auwerx J: Transient increase in obese gene expression after food intake or insulin administration. *Nature* 377:527–529, 1995
5. Barr VA, Malide D, Zarnowski MJ, Taylor SI, Cushman SW: Insulin stimulates both leptin secretion and production by rat white adipose tissue. *Endocrinol* 138:4463–4472, 1997
6. Bradley RL, Cheatham B: Regulation of *ob* gene expression and leptin secretion by insulin and dexamethasone in rat adipocytes. *Diabetes* 48:272–278, 1999
7. Mueller WM, Gregoire FM, Stanhope KL, Mobbs CV, Mizuno TM, Warden CH, Stern JS, Havel PJ: Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes. *Endocrinol* 139:551–558, 1998
8. Rossetti L: Perspective: Hexosamines and nutrient sensing. *Endocrinol* 141:1922–1925, 2000
9. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L: A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. *Nature* 393:684–688, 1998
10. Hebert LF, Daniels MC, Zhou J, Crook ED, Turner RL, Simmons ST, Neidigh JL, Zhu JS, Baron AD, McClain AD: Overexpression of glutamine: fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. *J Clin Invest* 98:930–936, 1996
11. McClain DA, Alexander T, Cooksey RC, Considine RV: Hexosamines stimulate leptin production in transgenic mice. *Endocrinol* 141:1999–2002, 2000
12. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like

- factor, apM1 (adipose most abundant gene transcript 1). *Biochem Biophys Res Commun* 221:286–289, 1996
13. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. *J Biol Chem* 270:26746–26749, 1995
 14. Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. *J Biol Chem* 271:10697–10703, 1996
 15. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. *J Biochem (Tokyo)* 120:802–812, 1996
 16. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun* 257:79–83, 1999
 17. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol* 20:1595–1599, 2000
 18. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Mary RS: Erickson MRS, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. *Proc Natl Acad Sci U S A* 98:2005–2010, 2001
 19. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Abe M, Tanaka J, Ohsumi J, Ide T, Murakami K, Kagechika H, Shudo K, Akanuma Y, Nagai R, Gavrilova O, Vinson C, Reitman ML, Yoda M, Nakano Y, Tobe K, Kimura S, Tomita M, Froguel P, Kadowaki T: Replenishment of the fat-derived hormone adiponectin reverses insulin resistance in lipotrophic diabetes and type 2 diabetes. *Nat Med* 7:941–946, 2001
 20. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. *Nat Med* 7:947–953, 2001
 21. Bogan JS, Lodish HF: Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. *J Cell Biol* 146:609–620, 1999
 22. Carpenter CL, Cantley LC: Phosphoinositide kinases. *Curr Opin Cell Biol* 8:153–158, 1996
 23. Kadowaki T, Tobe K, Honda-Yamamoto R, Tamemoto H, Kaburagi Y, Momomura K, Ueki K, Takahashi Y, Yamauchi T, Akanuma Y, Yazaki Y: Signal transduction mechanism of insulin and insulin-like growth factor-1. *Endocrine J* 43:S33–S41, 1996
 24. Escobedo JA, Navankasattusas S, Kavanaugh WM, Milfay D, Fried VA, Williams LT: cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF β -receptor. *Cell* 65:75–82, 1991
 25. Otsu M, Hiles I, Gout I, Fry MJ, Ruiz-Larrea F, Panayotou G, Thompson A, Dhand R, Hsuan J, Totty N, Smith AD, Morgan SJ, Courtneige SA, Parker PJ, Waterfield MD: Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complex, and PI3-kinase. *Cell* 65:91–104, 1991
 26. Skolnik EY, Margolis B, Mohammadi M, Lowenstein E, Fisher R, Drepps A, Ullrich A, Schlessinger J: Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. *Cell* 65:83–90, 1991
 27. Terauchi Y, Tsuji Y, Satoh S, Minoura H, Murakami K, Okuno A, Inukai K, Asano T, Kaburagi Y, Ueki K, Nakajima H, Hanafusa T, Matsuzawa Y, Sekihara H, Yin Y, Barrett JC, Oda H, Ishikawa T, Akanuma Y, Komuro I, Suzuki M, Yamamura K, Kodama T, Suzuki H, Koyasu S, Aizawa S, Tobe K, Fukui Y, Yazaki Y, Kadowaki T: Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 α subunit of phosphoinositide 3-kinase. *Nat Genet* 21:230–235, 1999
 28. Fruman DA, Mauvais-Jarvis F, Pollard DA, Yballe CM, Brazil D, Bronson RT, Kahn CR, Cantley LC: Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 α . *Nat Genet* 26:379–382, 2000
 29. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR: Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. *Mol Cell Biol* 22:965–977, 2002
 30. Shepherd PR, Gnudi L, Tozzo E, Yang H, Leach F, Kahn BB: Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. *J Biol Chem* 268:22243–22246, 1993
 31. Terauchi Y, Iwamoto K, Tamemoto H, Komeda K, Ishii C, Kanazawa Y, Asanuma N, Aizawa T, Akanuma Y, Yasuda K, Kodama T, Tobe Y, Yazaki Y, Kadowaki T: Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and β -cell glucokinase genes. *J Clin Invest* 99:861–866, 1997
 32. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto T, Okuno A, Murakami K, Ezaki O, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Aizawa S, Nagai R, Tobe K, Kimura S, Kadowaki T: PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. *Mol Cell* 4:597–609, 1999
 33. Giaccari A, Rossetti L: Isocratic high-performance liquid chromatographic determination of the concentration and specific radioactivity of phosphoenolpyruvate and uridine diphosphate glucose in tissue extracts. *J Chromatogr* 497:69–78, 1989
 34. Giaccari A, Rossetti L: Predominant role of gluconeogenesis in the hepatic glycogen repletion of diabetic rats. *J Clin Invest* 89:36–45, 1992
 35. Lagunas R, Diez-Masa JC: Separation and analysis of 4'-epimeric UDP-sugars by ion-pair reversed-phase HPLC. *Anal Biochem* 216:188–194, 1994
 36. Ikemoto S, Thompson KS, Takahashi M, Itakura H, Lane MD, Ezaki O: High fat diet-induced hyperglycemia: prevention by low level expression of a glucose transporter (GLUT4) minigene in transgenic mice. *Proc Natl Acad Sci U S A* 92:3096–3099, 1995
 37. Yamauchi T, Tobe K, Tamemoto H, Ueki K, Kaburagi Y, Yamamoto-Honda R, Takahashi Y, Yoshizawa F, Aizawa S, Akanuma Y, Sonenberg N, Yazaki Y, Kadowaki T: Insulin signalling and insulin actions in the muscle and liver of insulin resistant, IRS-1 deficient mice. *Mol Cell Biol* 16:3074–3084, 1996
 38. Ogawa Y, Masuzaki H, Hosoda K, Aizawa-Abe M, Suga J, Suda M, Ebihara K, Iwai H, Matsuoka N, Satoh N, Odaka H, Kasuga H, Fujisawa Y, Inoue G, Nishimura H, Yoshimasa Y, Nakao K: Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. *Diabetes* 48:1822–1829, 1999
 39. Burks DJ, Font de Mora J, Schubert M, Withers DJ, Myers MG, Towery HH, Altamuro SL, Flint CL, White MF: IRS-2 pathways integrate female reproduction and energy homeostasis. *Nature* 407:377–382, 2000
 40. Tobe K, Suzuki R, Aoyama M, Yamauchi T, Kamon J, Kubota N, Terauchi Y, Matsui J, Akanuma Y, Kimura S, Tanaka J, Abe M, Ohsumi J, Nagai R, Kadowaki T: Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. *J Biol Chem* 276:38337–38340, 2001
 41. Brünig JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR: Role of brain insulin receptor in control of body weight and reproduction. *Science* 289:2122–2125, 2000
 42. Spanswick D, Smith MA, Mirshamsi S, Routh VH, Ashford ML: Insulin activates ATP-sensitive K⁺ channels in hypothalamic neurons of lean, but not obese rats. *Nat Neurosci* 3:757–758, 2000
 43. Spanswick D, Smith MA, Groppi VE, Logan SD, Ashford ML: Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels. *Nature* 390:521–525, 1997
 44. Niswender KD, Morton GJ, Stearns WH, Rhodes CJ, Myers MG, Schwartz MW: Key enzyme in leptin-induced anorexia. *Nature* 413:794–795, 2001
 45. Suzuki H, Terauchi Y, Fujiwara M, Aizawa S, Yazaki Y, Kadowaki T, Koyasu S: Xid-like immunodeficiency in mice with disruption of the p85 α subunit of phosphoinositide 3-kinase. *Science* 283:390–392, 1999
 46. Kolaczynski JW, Nye MR, Considine RV, Boden G, Nolan JJ, Henry R, Mudaliar SR, Olefsky J, Caro JF: Acute and chronic effects of insulin on leptin production in humans: studies in vivo and in vitro. *Diabetes* 45:699–701, 1996
 47. Gettys TW, Harkness PJ, Watson PM: The beta 3-adrenergic receptor inhibits insulin-stimulated leptin secretion from isolated rat adipocytes. *Endocrinol* 137:4054–4057, 1996
 48. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, Komeda K, Miki H, Kubota N, Terauchi Y, Tsuchida A, Tsuboyama-Kasaoka N, Yamauchi N, Ide T, Hori W, Kato S, Fukayama M, Akanuma Y, Ezaki O, Itai A, Nagai R, Kimura S, Tobe K, Kagechika H, Shudo K, Kadowaki T: Inhibition of RXR and PPAR γ ameliorates diet-induced obesity and type 2 diabetes. *J Clin Invest* 108:1001–1013, 2001